| Registry | NCT03283449 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional; na, single group, masking: none, diagnostic |
| Enrollment | 70 (Estimated) |
| Sponsor | University of Chicago (Other); collaborators: National Institute on Aging (NIA) |
| Conditions | Primary Progressive Aphasia With Suspected Alzheimer's Disease |
| Interventions | 18F-AV-1451, PET (Drug, device) |
| Dates | start 2016-02-01, primary completion 2025-02-28, completion 2025-02-28, first posted 2017-09-14, last updated 2025-04-06 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Primary Progressive Aphasia With Suspected Alzheimer's Disease All trials of 18F-AV-1451 All trials of PET
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| AV-1451 Recipients | Experimental | Drug: 18F-AV-1451; Device: PET | Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging. |
Sex: All, ages: 20 Years to 100 Years
Inclusion Criteria: * Must have primary progressive aphasia Exclusion Criteria: * Pregnancy * Breastfeeding * Receiving radiation clinically
| Facility | City | Country | Status |
|---|---|---|---|
| University of Chicago - American School Building | Chicago, Illinois | United States |
NIH grants: R01AG056258